): This proposal is designed to provide the applicant, Peter Nelson, with the scientific tools and career development necessary for a successful career in academic medicine and basic science. Dr. Nelson has completed a combined hematology and oncology fellowship and is currently conducting research in Dr. Leroy Hood's laboratory at the University of Washington. During the next five years, Dr. Nelson plans to continue his studies of molecular alterations in prostate carcinoma with Dr. Hood as his sponsor and research mentor. The university of Washington has many faculty member engaged in related studies whose advance and guidance will be available. An advisory panel has been assembled to oversee both the applicant's research and academic progress. For the duration of this award, Dr. Nelson will devote at least 75% time and effort towards the research plan as well as participating in national meetings, scientific symposia, and molecular biology course-work. This proposal aims to use high-throughput molecular biological methods to discover the specific genetic differences which are important in the progression of prostate cancer from a patent to an aggressive form, and further to androgen independent growth. High-density arrays of cDNA clones will be constructed to provide a solid-phase archive suitable for a comprehensive analysis of differentially expressed genes. These genetic differences may be used as markers which can aid in diagnosing clinically relevant prostate cancer, and predict the clinical course of a given cancer. Clearly, the management of prostate cancer would be greatly aided by the determination of genetic, biochemical, and epidemiological markers that would discriminate between those cancers best treated by intervention, and those best treated by watchful waiting.
The specific aims are to 1) Identify and quantitate alterations in the transcript levels of genes that associate with phenotypes of prostate cancer progress, 2) characterize the differentially expressed genes correlating with a progressive prostate cancer phenotype. 3) Compile and evaluate a panel of cancer-phenotype associated products for prognostic relevance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA075173-02
Application #
2896107
Study Section
Subcommittee G - Education (NCI)
Program Officer
Pond, Cynthia L
Project Start
1998-07-01
Project End
1999-07-31
Budget Start
1999-07-01
Budget End
1999-07-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Matsumura, Masazumi; Bhatt, Ami S; Andress, Dennis et al. (2005) Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 62:1-13
Martin, Daniel B; Gifford, David R; Wright, Michael E et al. (2004) Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 64:347-55
Clegg, Nigel; Ferguson, Camari; True, Lawrence D et al. (2003) Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 55:55-64
Lin, Biaoyang; White, James T; Utleg, Angelita G et al. (2003) Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium. Genomics 82:331-42
Moore, Stacy; Pritchard, Colin; Lin, Biaoyang et al. (2002) Isolation and characterization of the murine prostate short-chain dehydrogenase/reductase 1 (Psdr1) gene, a new member of the short-chain steroid dehydrogenase/reductase family. Gene 293:149-60
Bonham, Michael; Arnold, Hugh; Montgomery, Bruce et al. (2002) Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. Cancer Res 62:3920-4
Bonham, Michael J; Galkin, Anna; Montgomery, Bruce et al. (2002) Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst 94:1641-7
Nelson, Peter S; Pritchard, Colin; Abbott, Denise et al. (2002) The human (PEDB) and mouse (mPEDB) Prostate Expression Databases. Nucleic Acids Res 30:218-20
Clegg, Nigel; Eroglu, Burak; Ferguson, Camari et al. (2002) Digital expression profiles of the prostate androgen-response program. J Steroid Biochem Mol Biol 80:13-23
Nelson, Peter S (2002) Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles. Ann N Y Acad Sci 975:232-46

Showing the most recent 10 out of 24 publications